Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:02 pm Purchase |
2024-12-31 | 13G | Avalo Therapeutics, Inc. AVTX |
BIOTECHNOLOGY VALUE FUND L P | 1,038,542 9.990% |
71,243 (+7.37%) |
Filing History |
| 2024-12-31 4:13 pm Purchase |
2024-12-23 | 13G | Avalo Therapeutics, Inc. AVTX |
Affinity Healthcare Fund, LP | 550,765 5.300% |
550,765 (New Position) |
Filing History |
| 2024-11-14 6:23 pm Purchase |
2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX |
ORBIMED ADVISORS LLC | 967,000 9.900% |
967,000 (New Position) |
Filing History |
| 2024-11-14 12:05 pm Sale |
2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX |
Allostery Investments LP | 55,840 0.500% |
-22,415 (-28.64%) |
Filing History |
| 2024-11-07 5:00 pm Purchase |
2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX |
Patrick J. Crutcher | 549,467 5.600% |
438,616 (+395.68%) |
Filing History |
| 2024-10-07 8:06 pm Purchase |
2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX |
Ikarian Capital LLC | 970,359 10.020% |
970,359 (New Position) |
Filing History |
| 2024-08-23 4:34 pm Purchase |
2024-08-13 | 13G | Avalo Therapeutics, Inc. AVTX |
BIOTECHNOLOGY VALUE FUND L P | 967,299 9.990% |
967,299 (New Position) |
Filing History |
| 2024-08-23 4:16 pm Purchase |
2024-08-13 | 13G | Avalo Therapeutics, Inc. AVTX |
RA Capital Management, L.P. | 967,299 9.990% |
967,299 (New Position) |
Filing History |
| 2024-08-23 4:05 pm Purchase |
2024-08-13 | 13G | Avalo Therapeutics, Inc. AVTX |
Patrick J. Crutcher | 110,851 9.900% |
110,851 (New Position) |
Filing History |
| 2024-05-13 12:38 pm Purchase |
2024-05-01 | 13G | Avalo Therapeutics, Inc. AVTX |
Allostery Investments LP | 78,255 7.600% |
78,255 (New Position) |
Filing History |
| 2024-04-23 2:59 pm Purchase |
2024-03-27 | 13G | Avalo Therapeutics, Inc. AVTX |
Emerald Bioventures LLC | 58,346 5.600% |
58,346 (New Position) |
Filing History |
| 2024-04-05 4:00 pm Purchase |
2024-03-27 | 13G | Avalo Therapeutics, Inc. AVTX |
Deep Track Capital, LP | 114,775 9.990% |
114,775 (New Position) |
Filing History |
| 2024-02-14 9:13 pm Unchanged |
2023-12-31 | 13G | Avalo Therapeutics, Inc. AVTX |
Venrock Healthcare Capital Partners III L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:51 pm Purchase |
2023-12-31 | 13G | Avalo Therapeutics, Inc. AVTX |
Nantahala Capital Management, LLC | 42,100 4.900% |
39,372 (+1443.36%) |
Filing History |
| 2024-02-14 4:36 pm Purchase |
2023-12-31 | 13G | Avalo Therapeutics, Inc. AVTX |
GREAT POINT PARTNERS LLC | 2,085 0.260% |
2,085 (New Position) |
Filing History |
| 2024-02-14 10:02 am Purchase |
2023-12-31 | 13G | Avalo Therapeutics, Inc. AVTX |
Point72 Asset Management, L.P. | 2,500 0.300% |
2,500 (New Position) |
Filing History |
| 2023-06-29 08:22 am Sale |
2023-06-26 | 13G | Avalo Therapeutics, Inc. AVTX |
Caissa Capital Management ltd. | 0 0.000% |
-6,146 (Position Closed) |
Filing History |
| 2023-06-27 6:02 pm Sale |
2023-06-26 | 13D | Avalo Therapeutics, Inc. AVTX |
Armistice Capital, LLC | 2,597 4.990% |
-17,331 (-86.97%) |
Filing History |
| 2023-04-19 4:38 pm Purchase |
2023-04-18 | 13G | Avalo Therapeutics, Inc. AVTX |
Caissa Capital Management ltd. | 6,146 11.190% |
339 (+5.84%) |
Filing History |
| 2023-02-17 4:05 pm Purchase |
2023-02-07 | 13G | Avalo Therapeutics, Inc. AVTX |
Venrock Healthcare Capital Partners III L.P. | 5,635 9.990% |
5,635 (New Position) |
Filing History |